C. Hocking

发表

Can we accurately report PTEN status in advanced colorectal cancer?

T. Price, N. Tebbutt, A. Ruszkiewicz, 2014, BMC Cancer.

Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer

T. Price, C. Hocking, 2014, Therapeutic advances in gastroenterology.

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

C. Porta, M. Burotto, R. Motzer, 2022, The Lancet. Oncology.

Comparable survival outcome of metastatic colorectal cancer in Indigenous and non-Indigenous patients: Retrospective analysis of the South Australian metastatic colorectal cancer registry.

G. Maddern, D. Roder, C. Karapetis, 2016, The Australian journal of rural health.

Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South Australia

G. Maddern, C. Karapetis, T. Price, 2014, The Medical journal of Australia.

Early discharge and ambulatory care of low‐risk patients with neutropenic fever in Australia

C. Hocking, A. Taylor, A. Hayward, 2013, Internal medicine journal.

Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies

S. Kumar, T. Price, J. Hardingham, 2014 .

Panitumumab in metastatic colorectal cancer

T. Price, C. Hocking, A. Townsend, 2013, Expert review of anticancer therapy.

Increasing chemotherapeutic and targeted drug options has led to improved overall survival in metastatic colorectal cancer. Panitumumab is a fully humanized monoclonal antibody that binds to the EGF receptor and inhibits downstream cell signaling with net effects

T. Price, C. Hocking, 2013 .

Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

T. Choueiri, N. Agarwal, A. Alva, 2022, The Journal of urology.

Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer

D. Cunningham, T. Price, N. Tebbutt, 2014, International journal of cancer.

A Prospective Audit of Inpatient Medical Oncology Consultation Patterns in a Tertiary Teaching Hospital in South Australia

D. Keefe, C. Hocking, S. O’neill, 2014 .

Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review

G. Kichenadasse, C. Hocking, 2014, Supportive Care in Cancer.

S. Gibbs, R. Chalwin, C. Hocking, 2022, Internal Medicine Journal.

South Australia

R. Chalwin, C. Hocking, Darren Lee, 1911, Internal Medicine Journal.

Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.

C. Porta, M. Burotto, R. Motzer, 2022, Journal of Clinical Oncology.